User profiles for Edmund Capparelli
Edmund CapparelliProfessor of Clinical Pediatrics and Pharmacy, University of California San Diego Verified email at ucsd.edu Cited by 18001 |
Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system
S Letendre, J Marquie-Beck, E Capparelli… - Archives of …, 2008 - jamanetwork.com
Objective To evaluate whether penetration of a combination regimen into the central
nervous system (CNS), as estimated by the CNS Penetration-Effectiveness (CPE) rank, is …
nervous system (CNS), as estimated by the CNS Penetration-Effectiveness (CPE) rank, is …
[HTML][HTML] Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy
…, D Masur, PO Clark, EV Capparelli… - … England Journal of …, 2010 - Mass Medical Soc
Background Childhood absence epilepsy, the most common pediatric epilepsy syndrome,
is usually treated with ethosuximide, valproic acid, or lamotrigine. The most efficacious and …
is usually treated with ethosuximide, valproic acid, or lamotrigine. The most efficacious and …
Intravenous gamma-globulin treatment and retreatment in Kawasaki disease
JC Burns, EV Capparelli, JA Brown… - The Pediatric …, 1998 - journals.lww.com
Objective. To determine the prevalence and outcome of intravenous gamma-globulin (IVIG)
retreatment in patients with Kawasaki disease (KD). Method. Multicenter, retrospective …
retreatment in patients with Kawasaki disease (KD). Method. Multicenter, retrospective …
[HTML][HTML] Effect of HIV antibody VRC01 on viral rebound after treatment interruption
…, JE Ledgerwood, EV Capparelli… - … England Journal of …, 2016 - Mass Medical Soc
Background The discovery of potent and broadly neutralizing antibodies (bNAbs) against
human immunodeficiency virus (HIV) has made passive immunization a potential strategy for …
human immunodeficiency virus (HIV) has made passive immunization a potential strategy for …
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
…, RA Koup, DC Douek, Z Hu, E Capparelli… - Science translational …, 2015 - science.org
Passive immunization with HIV-1–neutralizing monoclonal antibodies (mAbs) is being
considered for prevention and treatment of HIV-1 infection. As therapeutic agents, mAbs could be …
considered for prevention and treatment of HIV-1 infection. As therapeutic agents, mAbs could be …
Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study
…, T Alexander, S Letendre, E Capparelli… - Clinical Infectious …, 2015 - academic.oup.com
Background. Human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND)
can show variable clinical trajectories. Previous longitudinal studies of HAND typically …
can show variable clinical trajectories. Previous longitudinal studies of HAND typically …
Summary proceedings from the neonatal pain-control group
…, CB Berde, SA Buckman, EV Capparelli… - …, 2006 - publications.aap.org
Recent advances in neurobiology and clinical medicine have established that the fetus and
newborn may experience acute, established, and chronic pain. They respond to such …
newborn may experience acute, established, and chronic pain. They respond to such …
[HTML][HTML] Low-dose subcutaneous or intravenous monoclonal antibody to prevent malaria
…, S Vazquez, S Telscher, EV Capparelli… - … England Journal of …, 2022 - Mass Medical Soc
Background New approaches for the prevention and elimination of malaria, a leading cause
of illness and death among infants and young children globally, are needed. Methods We …
of illness and death among infants and young children globally, are needed. Methods We …
[HTML][HTML] A monoclonal antibody for malaria prevention
…, BJ Flynn, NK Kisalu, EV Capparelli… - … England Journal of …, 2021 - Mass Medical Soc
Background Additional interventions are needed to reduce the morbidity and mortality caused
by malaria. Methods We conducted a two-part, phase 1 clinical trial to assess the safety …
by malaria. Methods We conducted a two-part, phase 1 clinical trial to assess the safety …
Infliximab treatment of intravenous immunoglobulin–resistant Kawasaki disease
…, BI Asmar, DJ Lang, JD Connor, EV Capparelli… - The Journal of …, 2008 - Elsevier
OBJECTIVE: To investigate the safety, tolerability, and pharmacokinetics of the anti–tumor
necrosis factor-α monoclonal antibody infliximab in subjects with intravenous immunoglobulin …
necrosis factor-α monoclonal antibody infliximab in subjects with intravenous immunoglobulin …